Drugs / FORX-428
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07356453 | Jul 2025 → Jun 2027 expected | cancer | FoRx Therapeutics AG | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-26 | FoRx Therapeutics AG | Results FoRx Therapeutics Presents Preclinical Data at ACS Spring 2026, Confirming FORX-428’s Potential for Best-in-Class PARG Inhibition forxtherapeutics.com ↗
Data presented at ACS Spring 2026 showed FORX-428’s differentiated preclinical profile relative to a competitor reference compound, including superior selectivity and pharmacokinetics (PK), with potency shown to be at least 10-fold higher across multiple solid tumor cell lines. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-26 | FoRx Therapeutics AG | FoRx Therapeutics Presents Preclinical Data at ACS Spring 2026, Confirming FORX-428’s Potential for Best-in-Class PARG Inhibition forxtherapeutics.com ↗ |
| 2025-08-11 | FoRx Therapeutics AG | FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response forxtherapeutics.com ↗ |
| 2024-05-03 | FoRx Therapeutics AG | FoRx Therapeutics Announces Development Candidate Nomination of Potential Best-in-Class PARG Inhibitor FORX-428 forxtherapeutics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FORX-428 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07356453 ↗ |
| Action | Inhibit | “PARG Inhibitor FORX-428” NCT07356453 ↗ |
| Route | Oral | “FORX-428 drug product is formulated as immediate release tablets for oral administration” NCT07356453 ↗ |
| Target | PARG | “PARG Inhibitor FORX-428” NCT07356453 ↗ |